Download PDF
Thromb Haemost 1990; 64(04): 526-534
DOI: 10.1055/s-0038-1647352
Original Article
Schattauer GmbH Stuttgart

Prevention of Reocclusion by MCI-9038, a Thrombin Inhibitor, Following t-PA-lnduced Thrombolysis in a Canine Model of Femoral Arterial Thrombosis

Michael J Mellott
The Departments of Pharmacology and Biological Chemistry, Merck Sharp and Dohme Research Laboratories, West Point, PA, U.S.A.
,
Thomas M Connolly
The Departments of Pharmacology and Biological Chemistry, Merck Sharp and Dohme Research Laboratories, West Point, PA, U.S.A.
,
Sally J York
The Departments of Pharmacology and Biological Chemistry, Merck Sharp and Dohme Research Laboratories, West Point, PA, U.S.A.
,
Larry R Bush
The Departments of Pharmacology and Biological Chemistry, Merck Sharp and Dohme Research Laboratories, West Point, PA, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 16 February 1990

Accepted after revision13 July 1990

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We compared a selective thrombin inhibitor (MCI-9038; Argatroban), a thromboxane A2 (TXA2) receptor antagonist (L-670,596) and a serotonin-2 receptor antagonist (ketanserin) for their ability to hasten clot lysis and delay reocclusion in a canine model of femoral arterial thrombosis. Occlusive thrombosis was induced by insertion of a thrombogenic copper coil. Femoral arterial blood flow velocity (FABFV) was monitored directly and continuously by Doppler flowmetry. Thrombolysis was induced with tissue plasminogen activator (t-PA; 0.8 mg/kg, i.v.), starting 60 min after thrombotic occlusion and continued for 90 min. Ten minutes after occlusion, dogs received an intravenous infusion of either vehicle, MCI-9038 (10 Μ;g kg−1 min−1), ketanserin (0.1 mg/ kg bolus plus 5 pg kg−1 min−1), D670,596 (1 mg/kg bolus plus 17 pg kg−1 min−1) or a combination of D670,596 and ketanserin. All infusions were discontinued 1 h after stopping the t-PA, and were followed by a 30 min observation period. The times to thrombolysis were similar for all treatments (mean ± SEM = 47 ± 3; all groups). MCI-9038 prevented reocclusion, defined as permanent cessation of FABFV during the hour after stopping the t-PA. All dogs receiving MCI-9038 reoccluded within 30 min after stopping its infusion (71 ± 3 min). Reocclusion occurred in all other dogs, except one vehicle-treated dog and a second dog that received L-670,596 plus ketanserin. Vehicle-treated dogs reoccluded within 23 ± 8 min. Reocclusion was not delayed significantly by ketanserin, L-670,596 or the combination of the two. Thus, in this model, MCI-9038 prevented reocclusion, suggesting that thrombin may be an important mediator of arterial rethrombosis after t-PA-induced thrombolysis.

 

  • References

  • 1 Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Collen D. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986; 58: 673-679
    CrossrefPubMedGoogle Scholar
  • 2 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AF, Hutter Jr AM, Bell WR, Spadaro Jr JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective randomized; placebo-controlled trial. Circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 3 Verstraete M, Brower RW, Collen D, Dunning AJ, Lubsen J, Michel PL, Schofer J, Vanhaecke J, van de Werf F, Bleifeld WH, Charbonnier B, de Bono DP, Lennane RJ, Matjey DG, Raynaud Ph, Vahanian A, Van de Kley GA, von Essen R. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 2: 965-969
    PubMedGoogle Scholar
  • 4 Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, Brower RW, de Bono DP, Huhmann W, Lubsen J, Meyer J, Rutsch W, Schmidt W, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 2: 842-847
    PubMedGoogle Scholar
  • 5 Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794
    CrossrefPubMedGoogle Scholar
  • 6 Bush LR, Buja LM, Samowitz Q, Rude RE, Wathen M, Tilton GD, Willerson JT. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Circ Res 1983; 53: 248-263
    CrossrefPubMedGoogle Scholar
  • 7 Bergmann SR, Lerch RA, Fox KA A, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 1982; 73: 573-581
    CrossrefPubMedGoogle Scholar
  • 8 Gissi Study Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401
    PubMedGoogle Scholar
  • 9 Surreys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, Bar F, Zwaan C, Krauss XH, Remme WJ, Res J, Verheught FW A, van Domburg R, Lubsen J, Hugenholtz PG. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986; 7: 729-742
    CrossrefPubMedGoogle Scholar
  • 10 Chesebo JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154
    CrossrefPubMedGoogle Scholar
  • 11 Williams DO, Borer J, Braunwald E, Cheseboro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, Markis JE, Mueller H, Desvigne-Nickens P, Passamani ER, Powers ER, Rao AK, Roberts R, Ross A, Ryan TJ, Sobel BE, Winniford M, Zaret B. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338-746
    CrossrefPubMedGoogle Scholar
  • 12 Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Kanke M, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-352
    CrossrefPubMedGoogle Scholar
  • 13 Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, Kanke M, Collen D. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987; 9: 599-607
    CrossrefPubMedGoogle Scholar
  • 14 Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984; 69: 1161-1170
    CrossrefPubMedGoogle Scholar
  • 15 Ashton JH, Schmitz JM, Campbell WB, Ogeltree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/Prostaglandin H2 receptor antagonists. Circ Res 1986; 59: 568-578
    CrossrefPubMedGoogle Scholar
  • 16 Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT. The effects of alpha2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 1984; 55: 642-652
    CrossrefPubMedGoogle Scholar
  • 17 Benedict CR, Mathew B, Rex KA, Cartwright Jr J, Sorhahl LA. Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ Res 1986; 58: 58-67
    CrossrefPubMedGoogle Scholar
  • 18 Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572-578
    CrossrefPubMedGoogle Scholar
  • 19 Kaiser B, Hauptmann J, Marckwardt F. The pharmacokinetics of synthetic thrombin inhibitors of the basic type substituted n-alpha arylsulphonylated phenylalanine amide. Pharmazie 1987; 42: 119-121
    PubMedGoogle Scholar
  • 20 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-propyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
    CrossrefPubMedGoogle Scholar
  • 21 Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27
    CrossrefPubMedGoogle Scholar
  • 22 Hantgan RR, Francis CW, Scherega HA, Marder VJ. Fibrinogen structure and physiology. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) JB Lippincott; Philadelphia: 1987. pp 269-288
  • 23 McDonagh J. Structure and function of factor XIII. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) JB Lippincott; Philadelphia: 1987. pp 289-300
  • 24 Sakata Y, Aoko N. Cross-linking of alpha2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297
    CrossrefPubMedGoogle Scholar
  • 25 Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85-94
    CrossrefPubMedGoogle Scholar
  • 26 Machovich R. Thrombin and Hemostasis. In: The Thrombin Machovich R. (ed) CRC Press, Inc; Boca Raton, FL: 1984. Vol I pp 1-22
  • 27 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 77: 616-620
    PubMedGoogle Scholar
  • 28 Okamoto S, Hijikata A. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446
    CrossrefPubMedGoogle Scholar
  • 29 Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R, 4R)-4-Methyl-1-[N2-[(3-methyl-l,2,3,4-tetrahydro-8-quinolinyl)sul-fonyl]-L-arginyl]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90
    CrossrefPubMedGoogle Scholar
  • 30 Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemostas 1986; 56: 28-34
    PubMedGoogle Scholar
  • 31 Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986; 77496-77502
    PubMedGoogle Scholar
  • 32 Van der Giessen WJ, Zijlstra FJ, Berk L, Verdouw PD. The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig. Eur J Pharmacol 1988; 147: 241-248
    CrossrefPubMedGoogle Scholar
  • 33 Shebuski RJ, Smith Jr JM, Storer BL, Granett JR, Gugelski PJ. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharmacol Exp Ther 1988; 246: 790-796
    PubMedGoogle Scholar
  • 34 Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678-684
    CrossrefPubMedGoogle Scholar
  • 35 Van Nueten JM, Janssen PA J, Symoens J, Jansens WJ, Heykants J, DeClerck F, Leysen JE, Vancauteren H, Vanhoutte PM. Ketanserin. In: New Cardiovascular Drugs Scriabine A. (ed) Raven Press; New York: 1987. pp 1-56
  • 36 Bush LR, Mellott MJ, Kanovsky SM, Holahan MA, Patrick DH. A model of femorary artery thrombolysis in dogs. Fibrinolysis 1989; 3: 107-114
    PubMedGoogle Scholar
  • 37 Ford-Hutchinson AW, Girard Y, Lord A, Jones TR, Cirino M, Evans JF, Gillard J, Hamel P, Leveille C, Masson P, Young R. L-670,596: The pharmacology of a potent and selective thromboxane/ prostaglandin endoperoxide receptor antagonist. Can J Physiol Pharmacol 1989; 67: 989-993
    CrossrefPubMedGoogle Scholar
  • 38 Hartley CJ, Cole JS. An ultrasonic pulsed Doppler system for measuring blood flow in small vessels. J Appl Physiol 1974; 37: 626-629
    CrossrefPubMedGoogle Scholar
  • 39 Freed D, Hartley CJ, Christman KD, Lyman RC, Agris J, Walker WF. High frequency pulsed Doppler ultrasound: a new tool for microvascular surgery. J Microsurg 1979; 1: 148-153
    CrossrefPubMedGoogle Scholar
  • 40 Van Orden DE, Farley DB, Fastenow C, Brody MJ. A technique for monitoring blood flow changes with miniaturized Doppler flow probes. Am J Physiol 1984; 247 H 1005-1009
    PubMedGoogle Scholar
  • 41 Markwardt F. Pharmacological approaches to thrombin regulation. Ann NY Acad Sci 1986; 485: 204-214
    CrossrefPubMedGoogle Scholar
  • 42 Coleman RA, Humphrey PP A, Kennedy I, Levy GP, Lumley P. U46619, a selective thromboxane A2-like agonist?. Br J Pharmacol 1980; 69: 265-266
    CrossrefPubMedGoogle Scholar
  • 43 Bush LR, Smith S. Antagonism of U46619-induced aggregation of human and canine platelets by four thromboxane A2 (TXA2) receptor antagonists. Thromb Res 1986; 44: 377-389
    CrossrefPubMedGoogle Scholar
  • 44 Bush LR. Effects of the serotonin antagonists cyproheptadine, ketanserin, and mianserin, on cyclic flow reductions in stenosed canine coronary arteries. J Pharmacol Exp Ther 1986; 240: 674-682
    PubMedGoogle Scholar
  • 45 Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370
    CrossrefPubMedGoogle Scholar
  • 46 Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990; 4: 3087-3098
    CrossrefPubMedGoogle Scholar
  • 47 Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
    CrossrefPubMedGoogle Scholar
  • 48 Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-1262
    CrossrefPubMedGoogle Scholar
  • 49 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-665
    CrossrefPubMedGoogle Scholar
  • 50 Rosenberg RD. Heparin-antithrombin system. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice Colman RW, Hirsch J, Marder VJ, Salzman EW. (eds) JP Lippincott; Philadelphia, PA: 1987. pp 962-985
  • 51 Topol EJ, George BS, Kerieiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM. TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281-286
    CrossrefPubMedGoogle Scholar
  • 52 Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Plelletier E, Juneau M, Stasiak J, DeGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat unstable angina. N Eng J Med 1988; 319: 1105-1111
    CrossrefPubMedGoogle Scholar
  • 53 Leidy EM, Stem AM, Friedman PA, Bush LR. Enhanced thrombolysis by a Factor XHIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res 1990; 59: 15-26
    CrossrefPubMedGoogle Scholar
  • 54 Bush LR, Friedman PA, Mellott MJ, Kanovsky SM, Stern AM. Enhanced thrombolysis in vivo by a specific Factor XHIa inhibitor. Fibrinolysis 1988; 2 (Suppl) 4
    PubMedGoogle Scholar
  • 55 Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980; 17: 841-853
    CrossrefPubMedGoogle Scholar
  • 56 De ClerckF, Xhonneux B, Van GorpL, Beetens J, Jansen PA J. S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin endoperoxide receptor blockade (BM 13.177): enhanced anti-platelet effect. Thromb Haemostas 1986; 56: 236
    PubMedGoogle Scholar
  • 57 Schumaker WA, Lee EC, Lucchesi BR. Augmentation of streptokinase induced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 1085; 7: 739-746
    PubMedGoogle Scholar
  • 58 Cercek B, Lew AS, Hod H, Yano J, Reddy J, Reddy NK N, Ganz W. Enhancement of thrombolysis with tissue plasminogen activator by pretreatment with heparin. Am Heart J 1986; 74: 583-587
    PubMedGoogle Scholar
  • 59 Bush LR, Holahan MA, Kanovsky SM, Mellott MJ, Garsky VM, Gould RJ. Antithrombotic profile of echistatin, a snake venom peptide and platelet fibrinogen receptor antagonist in the dog. Circulation 1989; 80 (Suppl II) 11-23
    PubMedGoogle Scholar